Physiologic tailoring of treatment in resistant hypertension

Current Cardiology Reviews

Volumn 6, Issue 2, 2010, Pages 119-123

  David Spence, J ^a  

^a Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

African American; Amiloride; Primary hyperaldosteronism; Renal sodium channel; Renin; Resistant hypertension; Stroke belt

Indexed keywords

ALDOSTERONE; ALISKIREN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; EPLERENONE; RENIN; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MALE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; SECONDARY HYPERALDOSTERONISM;

EID: 77951601349     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310791162695     Document Type: Review

References (45)

1. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment and control of hypertension in Canada. Am J Hypertens 1997; 10(1097): 1102.
2. Petrella RJ, Merikle EP, Jones J. Prevalence, treatment, and control of hypertension in primary care: gaps, trends, and opportunities. J Clin Hypertens (Greenwich ) 2007; 9(1): 28-35.
3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43(1): 10-17
4. Lindhorst J, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview. Cardiovasc J Afr 2007; 18(4): 241-247
5. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation 2005; 112(23): 3562-3568
6. Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the Reasons for Geographic And Racial Differences in Stroke study. Stroke 2006; 37(5): 1171-1178 (Pubitemid 43731857)
7. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics-2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486
8. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2(6): 757-764
9. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 1-11.
10. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18(6): 649-656
11. Wong DG, Spence JD, Lamki L, McDonald JWD. Effect of nonsteroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1(8488): 997-1001.
12. White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009; 104(6): 840-845
13. Li C, Engström G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 2005; 36: 725-730
14. Spence JD. Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke 1986; 17: 808-810
15. Bass MJ, McWhinney IR, Donner A. Do family physicians need medical assistants to detect and manage hypertension? Can Med Assoc J 1986; 134: 1247-1255
16. Birkett NJ, Donner AP, Maynard M. Prevalence and control of hypertension in an Ontario county. Can Med Assoc J 1985; 132(9): 1019-1024
17. Wallach L, Nyarai I, Dawson KG. Stimulated renin: a screening test for hypertension. Ann Int Med 1975; 82: 27-34.
18. Spence JD. Physiologic tailoring of therapy for resistant hypertension:20 year' experience with stimulated renin profiling. Am J Hypertens 1999; 12: 1077-1083
19. Hackam DG, Thain LMF, Abassakoor A, McKenzie FN, Spence JD. Trapped renal arteries: Functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys. Can J Cardiol 2001; 17: 587-592
20. Spence JD. Treatment options for renovascular hypertension. Expert Opin Pharmacother 2002; 3: 411-416
21. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25): e510-e526.
22. Spence JD. Diagnosis of primary aldosteronism: for medical management, not just surgery. J Hypertens 2009; 27(1): 204-205
23. Rayner BL, Owen EP, King JA, et al. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. J Hypertens 2003; 21(5): 921-926
24. Baker EH, Duggal A, Dong Y, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension 2002; 40: 13-17
25. Swift PA, MacGregor GA. Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv Ren Replace Ther 2004; 11(1): 76-86.
26. Grim CE, Robinson M. Salt, slavery and survival- hypertension in the African diaspora. Epidemiology 2003; 14(1): 120-122
27. Russell RP, Masi AT. The prevalence of adrenal cortical hyperplasia at autopsy and its association with hypertension. Ann Intern Med 1970; 73(2): 195-205.
28. Biglieri EG, Kater CE, Arteaga EE. Primary aldosteronism is composed of primary adrenal hyperplasia and adenoma. J Hypertens 1984; 2(Suppl): S259-S261.
29. Sukor N, Mulatero P, Gordon RD, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 2008; 26(8): 1577-1582
30. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95(22): 1109-1119
31. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 betahydroxylase/ aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature 1992; 355(6357): 262-265
32. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009; 94(10): 3623-3630
33. Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2(1): 66-74.
34. Janmohamed S, Bouloux PM. The pharmacological treatment of primary aldosteronism. Expert Opin Pharmacother 2006; 7(5): 563-573
35. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19(4): 287-294
36. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligable aldosterone secretion. Trans Assoc Am Physicians 1963; 76: 199-213.
37. Warnock DG. Liddle syndrome: genetics and mechanisms of Na+ channel defects. Am J Med Sci 2001; 322(6): 302-307
38. Manunta P, Bianchi G. Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives - the adducin paradigm. J Am Soc Nephrol 2006; 17(4 Suppl 2): S30-S35.
39. Ferrandi M, Molinari I, Bianchi G, Ferrari P. Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension. Cell Mol Biol (Noisy -le-grand) 2006; 52(8): 15-18
40. Lacroix A, Bolte E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion-a new cause of Cushing's syndrome. N Engl J Med 1992; 327(14): 974-980
41. Wallach L, Nyarai I, Dawson KG. Stimulated renin: a screening test for hypertension. Ann Intern Med 1975; 82: 27-34.
42. Torres VE, Young WF, Jr., Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med 1990; 322(6): 345-351
43. Novello M, Catena C, Nadalini E, et al. Renal cysts and hypokalemia in primary aldosteronism: results of long-term followup after treatment. J Hypertens 2007; 25(7): 1443-1450
44. Egan BM, Basile JN, Rehman SU, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22(7): 792-801.
45. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51(2): 161-167